ResMed Management Performance

ResMed Inc -- USA Stock  

USD 88.9  0.11  0.12%

Analysis of ResMed manpower and management performance can provide insight into ResMed stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with ResMed Inc future performance. Additionally take a look at Your Equity Center.

ResMed Management Effectiveness

The company has Return on Asset of 8.72 % which means that on every $100 spent on asset it made $8.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.43 % implying that it generated $18.43 on every 100 dollars invested.

ResMed Profit Margins

The company has Net Profit Margin of 16.58 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 22.36 % which entails that for every 100 dollars of revenue it generated 0.22 of operating income.

ResMed Insider Trading

ResMed Stakeholders

Michael Farrell CEO and Director, MBA
Peter Farrell Non-Executive Chairman of the Board, Ph.D
BE Farrell Founder and Non-Executive Chairman
Jim Hollingshead President - Americas, Ph.D
Don Darkin President - Sleep-disordered Breathing Strategic Business Unit
Anne Reiser President Europe
Richard McHale President ? Respiratory Care
Donald Darkin President ? innovation & operations
Rob Douglas President COO
Raj Sodhi President ? Software as a Service (SaaS) Business and CTO, MBA
Brett Sandercock CFO and Principal Accounting Officer
Robert Douglas Pres and COO
John Wareham Independent Director, MBA
Ronald Taylor Lead Independent Director
Gary Pace Independent Director, Ph.D
Agnes Lee Senior Director - Investor Relations
Carol Burt Independent Director
Rich Sulpizio Independent Director
Jack Wareham Independent Director
Karen Drexler Director
Christopher Roberts Independent Director, MBA
Chris Roberts Independent Director, MBA
Ron Taylor Lead Independent Director
Richard Sulpizio Independent Director
David Pendarvis Chief Admin. Officer, Global General Counsel and Secretary

Leadership

ResMed Top Executives
Michael Farrell  CEO
CEO and Director
Peter Farrell  Chairman
Non-Executive Chairman of the Board

Tenure Analysis

ResMed Employment Tenure
ResMed employes about 5250 people. The company is managed by 25 executives with total tenure of roughly 157 years, averanging almost 6.0 years of service per executive having 210.0 employee per reported executive.

Earnings

ResMed Earnings Estimates
EPSEstimate Date
Quarterly Estimate0.7April 25, 2017
ResMed Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Manpower Efficiency

Return on ResMed Manpower
Revenue Per Employee 410.9 K
Revenue Per Executive 84.8 M
Net Income Per Employee 78.8 K
Net Income Per Executive 14.1 M
Working Capital Per Employee 148.9 K
Working Capital Per Executive 31.3 M

Per Employee

ResMed Per Employee Growth Over Time

Net Income Per Employee

Revenue Per Employee

Number of Employees

ResMed Number of Employees Analysis
ResMed Inc is rated below average in number of employees category among related companies. The total workforce of Medical Equipment industry is at this time estimated at about 102,112. ResMed holds roughly 5,250 in number of employees claiming about 5% of all equities under Medical Equipment industry.

Earnings Per Share

ResMed Inc Earnings Per Share
According to company disclosure ResMed Inc has Earnings Per Share of 2.46 times. This is 228.0% higher than that of the Healthcare sector, and significantly higher than that of Medical Equipment industry, The Earnings Per Share for all stocks is 6.96% lower than the firm.
Earnings per Share is one of the most important measures of the current share price of a firm, and is used by investors to determine the company overall profitability; especially when it is compared to the EPS of similar companies.